Damora Therapeutics, Inc.
DMRA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$21.09
KIRA · Stoqly’s AI analyst, in plain words
- Damora Therapeutics, Inc. had $1.2M of revenue in fiscal 2025, up 38.3% on the year before.
- Its operating margin was −18,069.6%, down 15,432.1 pts: of every 100 in sales, about −18,070 is left after running the business.
- Damora Therapeutics, Inc. lost $210M in fiscal 2025.
Market cap
$1.3B
P/E
2.8x
Revenue
$1.2M
Net income
−$210M
Free cash flow
—
Operating margin
−18,069.6%
Damora Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+38.3%
Yes. Sales grew 38.3% last year.
Does it make a profit?
−17,981.1%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
2.8x
One share costs 2.8 times its yearly profit per share.
What Damora Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Damora Therapeutics, Inc.
- CIK
- 0001800315
Damora Therapeutics, Inc. · DMRA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $0.7M | $1.7M | $0.8M | $1.2M |
| Revenue growth | — | 362.8% | 133.9% | −50.0% | 38.3% |
| Net interest income | $0.2M | $0.7M | $1.7M | $0.8M | $1.2M |
| Operating margin | −33,478.8% | −8,477.4% | −2,362.6% | −2,637.4% | −18,069.6% |
| Net income | −$51.8M | −$61.6M | −$38.3M | −$21.4M | −$210M |
| Net margin | −33,174.4% | −8,535.2% | −2,270.5% | −2,540.2% | −17,981.1% |
| Diluted EPS | −$2.05 | −$2.43 | −$36.08 | −$18.53 | $3.98 |
| Cash | |||||
| Cash from operations | −$52.3M | −$42.9M | −$36.9M | −$18.6M | −$6.7M |
| Capital expenditure | $0.2M | $0.2M | — | — | — |
| Free cash flow | −$52.5M | −$43.1M | — | — | — |
| FCF margin | −33,673.7% | −5,973.4% | — | — | — |
| Share count change | 452.4% | 0.6% | −95.8% | 8.9% | 17.8% |
| Debt and strength | |||||
| Cash and short-term investments | $100M | $60.2M | $33.2M | $14.2M | $258M |
| Shareholders' equity | $117M | $61.8M | $32.3M | $15.8M | $240M |
| Current ratio | 24.2x | 5.8x | 6.3x | 14.1x | 13.0x |
| Returns and quality | |||||
| Return on equity | −36.6% | −68.9% | −81.5% | −89.0% | −163.8% |
| Return on tangible equity | −44.1% | −99.8% | −118.6% | −135.4% | −87.3% |
| Piotroski F-score | — | 2 | 4 | 3 | 2 |
| Altman Z'' | 23.3 | −4.9 | −17.8 | −42.8 | 7.0 |
Insiders bought, 12 months
$0.3M
1 insider
Insiders sold, 12 months
$0.0M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Damora Therapeutics, Inc. · DMRA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $21.09 a share, the company is worth $1.3B: 2.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001800315). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.